Navigation Links
Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Date:10/22/2008

SAN FRANCISCO, Oct. 22 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its collaboration with Pfizer Inc. expired on October 20, 2008. Under the collaboration, Medivation and Pfizer have agreed to jointly develop and commercialize Dimebon for the treatment of Alzheimer's disease and Huntington's disease. Expiration of the waiting period triggers an up-front payment to Medivation of $225 million.

Under the terms of the collaboration agreement with Pfizer, Medivation also is eligible to receive payments of up to $500 million upon the attainment of development and regulatory milestones plus additional undisclosed commercial milestone payments. Medivation and Pfizer will collaborate on the Phase 3 program in Alzheimer's disease, Huntington's disease development and regulatory filings in the United States. The companies will share all U.S. development and commercialization expenses along with U.S. profits/losses on a 60 percent/40 percent basis, with Pfizer assuming the larger share of both expenses and profit/losses. In addition, Medivation will co-promote Dimebon to specialty physicians in the U.S. Pfizer will have responsibility for development, regulatory and commercialization outside the U.S. and will pay Medivation tiered royalties on commercial sales outside of the U.S.

About Dimebon

Results from the first pivotal trial of Dimebon in Alzheimer's disease showed that patients treated with Dimebon experienced statistically significant improvements compared to placebo in key aspects of the disease -- memory and thinking, activities of daily living, behavior and overall function. Dimebon's benefit over placebo con
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
3. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
6. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
7. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
8. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
9. Medivation Announces Senior Management Promotions
10. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
11. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information says ... Ebola concern in the United States ... The healthcare market researcher said the FDA,s Emergency Use Authorization ... diagnostic tests for the detection of the Ebola virus ... useful.  Kalorama routinely assess the IVD industry and its ...
(Date:10/27/2014)... Florida (PRWEB) October 27, 2014 ... at reducing and eliminating several types of pediatric ... not been achieved in over 30 years of ... Noah's Light Foundation, proves that one mom's determination ... diagnosed just before Halloween trick-or-treating, and it’s only ...
(Date:10/27/2014)... HORSHAM, Pa. , Oct. 27, 2014 /PRNewswire/ ... Colitis Foundation of America (CCFA) announced today the ... , an educational campaign designed ... bowel diseases (IBD) on the paired role of ... To view the multimedia assets associated with ...
(Date:10/26/2014)... The report "Protective Coatings Market by ... Trends & Forecast to 2019", defines and segments the ... volume consumed and value generated. The protective coatings consumption ... to 6,701.3 KT by 2019, at a CAGR of ... data tables and 22 figures spread through 219 slides ...
Breaking Biology Technology:Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4
... COLUMBIA, Md., May 22 Martek Biosciences,Corporation (Nasdaq: ... results,of its second quarter of fiscal 2008 on June ... the release, at 4:45 p.m. ET Martek will,conduct a ... quarter of,fiscal 2008 with investors. All interested parties may ...
... for profit, WASHINGTON, May 22 Medtronic ... to pay $75,000,000 to the federal government to,settle ... device,company,s sales and pricing strategy to increase its ... lawsuit, which the government joined, was,kept under seal ...
... Nektar,Therapeutics (Nasdaq: NKTR ) announced today ... as Chief Operating Officer and Head of the,PEGylation ... aspects of the PEGylation Business Unit, including research,and ... He will also,serve as Chairman of Nektar India ...
Cached Biology Technology:Medtronic Unit to Pay $75 Million to Settle Whistleblower Medicare Fraud Case 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 3
(Date:10/29/2014)... of its kind to date, researchers have used DNA ... risk for autism. Joseph Buxbaum, Ph.D., Icahn School of ... Ph.D., Broad Institute of Harvard and MIT, and their ... children, parents and unrelated people. They identified changes in ... risk for autism spectrum disorder (ASD) – a jump ...
(Date:10/29/2014)... Online registration is open for the ... Scientific Meeting. SIR 2015 is the one ... trainees and related health care professionals can ... image-guided science and technologies being presented, discussed ... community in minimally invasive, image-guided medicine, SIR ...
(Date:10/29/2014)... Plants rely on sunlight to make their food, but they ... do. Recently, scientists discovered a group of molecules in plants ... in the Journal of the American Chemical Society , ... plant sunscreens work. , Timothy Zwier and colleagues at Purdue ... to daily can cause serious damage to plant DNA and, ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... with a number of pathological conditions, including cancer. Publishing in ... in drinking water given at the maximum levels permitted ... in mice. On the other hand, reducing copper levels reduced ... essential factor for the growth of tumors in humans as ...
... Hall Institute have been awarded more than $2.2 million from ... disorders and inflammatory diseases. Three institute researchers - ... - were announced last week as recipients of ARC Future ... body controls errant immune cells that cause type 1 diabetes ...
... , Nov. 14, 2013  Based on its recent research ... presents Cognitec Systems GmbH with the 2013 European ... Cognitec,s blinkers-on focus on face biometrics earned the ... to develop its flagship face recognition technology, FaceVACS-VideoScan. ...
Cached Biology News:Copper intake makes tumors breathe 2ARC Future Fellows awarded $2.2M for immune and inflammation studies 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 3Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 4Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 5
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Homo sapiens formin-like...
Mouse Ameloblastin Biotinylated Affinity Purified PAb ENTREZ GeneID: 11698...
... GRASP1 ( Abpromise for all ... Synthetic peptide corresponding to amino ... region of rat GRASP1, conjugated to ... Entrez GeneID: 56850 ...
Biology Products: